AIDD is an integrated tool and a radically new way to discovery new drugs for neurodegenerative diseases (Alzheimer’s, Epilepsy, Ageing, etc.).
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 6 of 6
The virtual dynamic docking, carried out in the MOLBD3 lab of the Institute of Biophysics, allows the identification of new drugs through the structural information deriving from the study of target proteins, responsible for some human pathologies. In particular, we screen drugs or small molecules (commercial/own libraries) against known protein sites, surface cavities, surfaces of protein-protein interactions (fixed/rigid hotspots) or structural transition states (dynamic hotspots).
Mergers e Acquisitions represent important forms of business deals because of the volumes involved in the transactions and the role of the innovation activity of companies. By considering the patent activity of about one thousand companies, we develop a method to predict future acquisitions by assuming that companies deal more frequently with technologically related ones.
Recently, it has been demonstrated that Raman spectroscopy can play a fundamental role in assisting the work of the anatomopathologist by allowing classification of oncological samples with practically 100% accuracy in oncological diagnosis.
This is a high-throughput sequencing based method to map euchromatin and heterochromatin accessibility. The method is based on the sequential extraction of distinct nuclear fractions containing: soluble proteins (S1 fraction); the surnatant obtained after DNase treatment (S2 fraction); DNase-resistant chromatin extracted with high salt buffer (S3 fraction); and the most condensed and insoluble portion of chromatin, extracted with urea buffer that solubilizes the remaining proteins and membranes (S4 fraction).
VOLIS is an online platform that contains various tests for assessing Italian Sign Language (LIS) comprehension skills in signing children, from 4 to 11 years of age. The consequences of some difficulties such as deafness, cognitive impairments and autism spectrum disorder may affect learning, social interaction and broad communicative skills. The use of LIS may support children that have difficulties in acquiring and using a using spoken languages.